Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADhVN120304.H5

Next Previous
Search
Drug Profile

ADhVN120304.H5

Alternative Names: ADhVN1203/04.H5 - Altimmune; Influenza A vaccine H5N1 - Altimmune; Influenza A vaccine intranasal - Altimmune; Influenza-virus-vaccine-Vaxin; NasoVAX; Seasonal-influenza-virus-vaccine-intranasal-Vaxin

Latest Information Update: 22 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class COVID-19 vaccines; Influenza virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued COVID 2019 infections; Influenza A virus H5N1 subtype

Most Recent Events

  • 31 Dec 2021 Discontinued - Phase-II for COVID-2019 infections (In the elderly, In adults) in USA (Intranasal)
  • 31 Dec 2021 Discontinued - Phase-II for Influenza A virus H5N1 subtype (Prevention) in USA (Intranasal)
  • 10 Oct 2020 Altimmune terminates a phase II trial in COVID-2019 infections (In adults, In elderly) in USA due to enrolment (Intranasal) (NCT04442230)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top